Literature DB >> 18404864

Emerging topical antimicrobial options for mild-to-moderate acne: a review of the clinical evidence.

James Del Rosso1.   

Abstract

Topical antimicrobial agents are commonly used as first-line agents for the management of mild to moderate acne vulgaris. Agents with antibacterial activity (eg, benzoyl peroxide and clindamycin), reduce counts of Propionibacterium acnes, while also decreasing the numbers of inflammatory and noninflammatory lesions. In order to optimize efficacy, topical antibiotics are most commonly used in combination with benzoyl peroxide, an approach which also reduces the emergence of strains of P acnes that are less sensitive to antibiotics. Other topical antiacne options include retinoids (with or without an antimicrobial agent), sulfacetamide, sulfacetamide-sulfur, and azelaic acid. Certain formulations of benzoyl peroxide offer improved tolerability, while a new micronized form may enhance efficacy by optimizing follicular penetration. This wide array of options allows dermatologists to tailor topical treatments to the needs of individual patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404864

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  A 6% benzoyl peroxide foaming cloth cleanser used in the treatment of acne vulgaris: aesthetic characteristics, patient preference considerations, and impact on compliance with treatment.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2009-07

2.  Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro study of clinical isolates from a hospital in Shanghai, China.

Authors:  Ying Ma; Nanxue Zhang; Shi Wu; Haihui Huang; Yanpei Cao
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

3.  Suppression of Propionibacterium acnes Infection and the Associated Inflammatory Response by the Antimicrobial Peptide P5 in Mice.

Authors:  Sunhyo Ryu; Hyo Mi Han; Peter I Song; Cheryl A Armstrong; Yoonkyung Park
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.